Recent Updates — COCH
Envoy Medical implemented a 1-for-10 reverse stock split of its Class A common stock, which became effective on October 26, 2026. The action was authorized by shareholders at a special meeting on October 12, 2026, and approved by the board to maintain compliance with Nasdaq's $1.00 minimum bid price requirement. Every ten outstanding shares were combined into one share, with fractional shares paid out in cash. Exercise prices for warrants and convertible securities, as well as terms of stock incentive plans, were proportionately adjusted. The company operates in the hearing health and neuroprosthetics sector, developing fully implanted hearing solutions.
Envoy Medical entered into a Dismissal Agreement to resolve litigation in the Delaware Court of Chancery brought by Atlas Merchant Capital SPAC Fund I LP. The dispute centered on Atlas's allegation that it was improperly denied redemption rights for its Class A Common Stock shares during the company's September 2023 business combination transaction. Under the agreement, all claims are dismissed with prejudice and no further proceedings will occur. Crucially, neither Envoy Medical nor any other defendant is required to make a payment to Atlas. The company operates in the medical device industry, specializing in minimally invasive surgical instruments.
Envoy Medical appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance effective August 24, 2026. Mr. Potashnick receives a $315,000 annual base salary, a target bonus equal to 15% of base salary, and an initial equity award of 250,000 stock options at an exercise price of $0.746 per share. He previously served as the company's interim CFO on a contractor basis since June 2025. Envoy Medical develops and manufactures minimally invasive surgical devices for ear, nose, and throat procedures.
Envoy Medical, Inc. reported financial results for the second quarter ended June 30, 2026, including net revenue of $51,000 and a net loss attributable to common stockholders of $7,272,000, or $0.07 per share. The company submitted the first module of its modular Premarket Approval application for the Acclaim cochlear implant to the FDA and reported positive 12-month clinical data showing improved speech perception in early trial participants. Additionally, Envoy Medical terminated its at-the-market equity offering program, which had authorized up to $15 million in sales. As of June 30, 2026, the company held approximately $19.7 million in cash. Envoy Medical operates in the hearing health industry, developing and commercializing fully implanted medical devices for hearing loss.
Envoy Medical, Inc. terminated its At The Market Offering Agreement dated January 17, 2025, on June 24, 2026. Envoy Medical, Inc. is a medical device company that develops and manufactures specialized respiratory-related medical devices.
Envoy Medical, Inc. announced on June 19, 2026, that its Compensation Committee approved an updated base salary of $420,000 and a $105,000 target cash bonus for CEO Brent Lucas. The Committee also granted 1,000,000 stock options with an exercise price of $0.634 per share and 1,000,000 restricted stock units (RSUs) that vest upon FDA approval of the Acclaim cochlear implant between 06/19/2026 and 06/18/2030. Envoy Medical, Inc. operates in the medical device industry and develops cochlear implant technology.